The ROCKET study is a clinical research study that will help determine if an investigational medicine, called OV101 or gaboxadol, is safe and effective in treating behavioral characteristics commonly present in people with Fragile X syndrome (FXS). The study will test three different doses of OV101.
Participation in the ROCKET study will last approximately 21 weeks and include six visits to the study medical center and four phone appointments. The study center visits will last the majority of the day.
At the clinic appointments, you will meet with your study team, which will include a study physician, nurse, and other healthcare professionals. They will explain the study, answer your questions, and monitor your care.
The phone appointments will take place between visits to the study medical center. During these calls, a study team member will ask about any changes in your son’s health and behavior. You may also discuss any side effects or new symptoms your son may be experiencing and any new medicines or vitamins he may be taking.
Age: 13 to 22
Disorder: Confirmed diagnosis of Fragile X syndrome
He also needs to be able to swallow a capsule, or its contents when mixed with soft food; and must have a parent or caregiver who can provide consent, attend scheduled visits, and participate in study assessments and scheduled phone meetings.
- Phoenix, Arizona
- Sacramento, California
- Aurora, Colorado
- Chicago, Illinois
- Baltimore, Maryland
- Cincinnati, Ohio
- Media, Pennsylvania
- Nashville, Tennessee
Our Most Recent Opportunities
Individuals with FXS who are 18 years or older and able to talk fluently about own experiences, and their caregivers and providers may be eligible to participate. Eligible providers include teachers, psychologists, social workers, and physicians.
NFXF has partnered with an advisory committee of international fragile X professionals to create an international fragile X premutation research registry. Find out how to participate.
A Mount Sinai Genetic Counseling graduate student is conducting a research study to learn about possible benefits and side effects of CBD supplements when used to treat FXS symptoms. This information will be obtained by using an anonymous online parental and caregiver survey. About the Survey Who can participate? Parents and caregivers caring for somebody with FXS who uses, or has used, CBD supplements may be eligible to participate. The parent or caregiver responding to the survey must be at least 18 years old. The individual with ...
Researchers at Teachers College at Columbia University are conducting a survey to learn about the impact that the COVID-19 pandemic has had on multiple aspects of the lives of people with Fragile X Syndrome. We want to see how the Fragile X community specifically was impacted so that we can have a more focused plan of action for helping these families. The overall goal of this survey is to distribute our findings to medical professionals so that they can see what gaps have been created in their practices from the pandemic.
Participants of this study will explore what information is considered most important to recently diagnosed fragile X premutation carriers. Open to premutation carriers 18 and over who were diagnosed sometime since January 2018.
Kaylynn Shuleski, a master’s in genetic counseling candidate, is conducting a research study to explore the concerns and challenges caregivers may face when planning long-term supports and living arrangements for their adult children with Fragile X syndrome (FXS). This information will be valuable for current and future families when considering long-term supports, as well as for healthcare professionals, counselors, and policy makers. About the Study Who can participate? Parents and caregivers of adults with full mutation ...